Some buzzing pharma stocks including Cipla Ltd, Glenmark Pharmaceuticals Ltd and Lupin Ltd are likely to remain under the ...

Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency ...

Ramesh Swaminathan, Global CFO of Lupin discusses the impact of Trump's win on the Indian pharmaceutical sector. Growing ...

Lupin’s revenue was largely in-line with our estimates (+2.3%). EBITDA and Adj. PAT beat our estimates significantly due to ...

CEO Vinita Gupta stated that Lupin expects to maintain a quarterly range of $220-230 million for its US business, driven by ...

In the September quarter, the pharma major’s US sales dipped sequentially to $220 million against $227 million in Q1FY25.

Lupin Q2 Results Live : Lupin declared their Q2 results on November 7, 2024, reporting a robust performance with a topline ...

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2420 in its ...

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the ...

Shares of the Lupin Ltd. traded at Rs 2095.25 on BSE at 11:10AM (IST) on Monday, down 0.43 per cent. The stock quoted a ...

Lupin Limited delivered a strong financial performance for the second quarter, surpassing market expectations. Net profit for ...

Warner Bros. Discovery is adapting the Harry Potter novels all over again – this time as a TV series – and it’s hard to ...